Article Text

PDF
THU0390 Effect of Glucocorticoid Treatment on Wnt Signalling Antagonists (Sclerostin and Dkk-1) and their Relationship to Bone Turnover and Bone Mass
  1. L. Gifre1,
  2. P. Peris1,
  3. S. Ruiz-Gaspà2,
  4. A. Monegal1,
  5. B. Nomdedeu3,
  6. N. Guañabens1
  1. 1Metabolic Bone Diseases Unit. Rheumatology Department
  2. 2CIBERehd
  3. 3Hematology Department, Hospital Clinic Barcelona, Barcelona, Spain

Abstract

Background Wnt-ß-catenin signalling and its antagonists (sclerostin and Dkk-1) play an important role in the regulation of bone mass and osteoblastogenesis. Glucocorticoid therapy (GCCT) is a well known factor related to decreased bone formation and osteoporosis development.

Objectives To analyze the effect of GCCT on Wnt signalling antagonists (sclerostin and Dkk-1) and their relationship to bone mass and bone turnover.

Methods 22 patients (11M/11F, aged 48±20 yrs) recently initiating GCCT were prospectively included (≥7.5mg/day, ≤6months), excluding patients with associated metabolic bone diseases or on antiosteoporotic treatment. Bone turnover markers (Bone formation: P1NP, bone AP; Bone resorption: sCTx), Wnt antagonists (serum sclerostin and Dkk-1, determined by ELISA, Biomedica Gruppe, Austria) were assessed in all patients (at baseline and 12 months). Bone mineral density (BMD) was performed to assess osteoporosis. The results were compared with 20 healthy controls.

Results The mean daily GCCT dose was 66±16 mg/day. Idiopathic thrombocytopenic purpura (73%) and hemolytic anemia (14%) were the most frequently associated conditions. Patients on GCCT showed a significant decrease in bone formation markers versus controls (PINP: 19.6±9.4 vs. 44.1±8.9 ng/ml, p=0.001) and increased bone resorption (sCTx: 0.58±0.23 vs. 0.4±0.17 ng/mL, p=0.049). Patients on GCCT had decreased Dkk-1 compared to controls (31.8±28.1 vs. 46.8±15.3 pmol/L, p=0.028) with similar sclerostin values (39.7±21.3 vs. 32.9±19.3 pmol/L, p=0.399). 20% had densitometric osteoporosis. Sclerostin correlated positively with GCCT doses (r=0.505, p=0.016) and lumbar BMD (r=0.554, p=0.008), and negatively with bone AP (r=-0.510, p=0.015). At 12 months, Dkk-1 significantly decreased compared to baseline (16.6±13.8, p=0.02), and sclerostin tended to increase (49.2±12.0, p=0.496).

Conclusions The effect of GCCT on the serum levels of the Wnt signalling parameters differs depending on the antagonist evaluated. Dkk-1 levels decreased after the initiation of GCCT whereas sclerostin values tended to increase and showed a relationship to the dose of GCC and bone formation parameters.

Acknowledgements Work funded by a grant from Societat Catalana de Reumatologia.

Disclosure of Interest None Declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.